These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14559785)

  • 1. Extracellular proteolysis and cancer: meeting summary and future directions.
    Matrisian LM; Sledge GW; Mohla S
    Cancer Res; 2003 Oct; 63(19):6105-9. PubMed ID: 14559785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase inhibitors and cancer: trials and tribulations.
    Coussens LM; Fingleton B; Matrisian LM
    Science; 2002 Mar; 295(5564):2387-92. PubMed ID: 11923519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of matrix metalloproteinase inhibitors in cancer therapy.
    Purcell WT; Rudek MA; Hidalgo M
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1189-227. PubMed ID: 12512389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of matrix metalloproteinases in patients with malignant tumors].
    Stanciūte D; Didziapetriene J; Kadziauskas J
    Medicina (Kaunas); 2004; 40(12):1143-50. PubMed ID: 15630339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
    Levin M; Udi Y; Solomonov I; Sagi I
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological activity and clinical implications of the matrix metalloproteinases.
    Rydlova M; Holubec L; Ludvikova M; Kalfert D; Franekova J; Povysil C; Ludvikova M
    Anticancer Res; 2008; 28(2B):1389-97. PubMed ID: 18505085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects.
    Fingleton B
    Expert Opin Ther Targets; 2003 Jun; 7(3):385-97. PubMed ID: 12783574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?
    Mannello F
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):91-103. PubMed ID: 18221029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases.
    Fridman R
    Biochim Biophys Acta; 2010 Jan; 1803(1):1-2. PubMed ID: 20159302
    [No Abstract]   [Full Text] [Related]  

  • 10. Matrix metalloproteinases: roles in cancer and metastasis.
    Fingleton B
    Front Biosci; 2006 Jan; 11():479-91. PubMed ID: 16146745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinases. Novel targets for directed cancer therapy.
    Yu AE; Hewitt RE; Connor EW; Stetler-Stevenson WG
    Drugs Aging; 1997 Sep; 11(3):229-44. PubMed ID: 9303281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.
    Overall CM; Kleifeld O
    Nat Rev Cancer; 2006 Mar; 6(3):227-39. PubMed ID: 16498445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
    Li W; Saji S; Sato F; Noda M; Toi M
    Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there new hope for therapeutic matrix metalloproteinase inhibition?
    Vandenbroucke RE; Libert C
    Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MMP inhibitors and cancer treatment trials, limitations and hopes for the future.
    Tlatli R; El Ayeb M
    Arch Inst Pasteur Tunis; 2013; 90(1-4):3-21. PubMed ID: 26012207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis.
    Brown GT; Murray GI
    J Pathol; 2015 Nov; 237(3):273-81. PubMed ID: 26174849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
    Zucker S; Cao J; Chen WT
    Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.
    Pavlaki M; Zucker S
    Cancer Metastasis Rev; 2003; 22(2-3):177-203. PubMed ID: 12784996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase inhibitors--an emphasis on gastrointestinal malignancies.
    Chau I; Rigg A; Cunningham D
    Crit Rev Oncol Hematol; 2003 Feb; 45(2):151-76. PubMed ID: 12604127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
    Yang JS; Lin CW; Su SC; Yang SF
    Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.